PBREN D 75/20MG TABLET 10'S

PBREN D 75/20MG Tablet is primarily used to relieve pain and inflammation, especially in conditions like arthritis and other musculoskeletal conditions.

Common side effects may include abdominal pain, nausea, vomiting, diarrhea, and constipation. Consult a doctor if these side effects persist or become severe.

It is advisable to take PBREN D 75/20MG Tablet with food to minimize stomach irritation.

Store PBREN D 75/20MG Tablet at room temperature, away from direct sunlight and moisture. Keep out of reach of children and pets.

Pregnant women should consult a doctor before using PBREN D 75/20MG Tablet. It should only be used during pregnancy if clearly needed and prescribed by a doctor.

Breastfeeding women should consult a doctor before using PBREN D 75/20MG Tablet, as it may pass into breast milk.

If you miss a dose of PBREN D 75/20MG Tablet, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose.

PBREN D 75/20MG Tablet can interact with certain medications, such as blood thinners, other pain relievers, and certain antidepressants. Inform your doctor about all your medications to avoid any potential drug interactions.

An overdose of PBREN D 75/20MG Tablet can be dangerous and may cause serious side effects. In case of an overdose, seek immediate medical attention.

Alternatives to PBREN D 75/20MG Tablet include other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) which can be prescribed by the doctor.

It is not recommended to consume alcohol while taking PBREN D 75/20MG Tablet, as it may increase the risk of stomach bleeding.

The time it takes for PBREN D 75/20MG Tablet to work can vary from person to person. Generally, it starts providing pain relief within a couple of hours after taking it.

No, PBREN D 75/20MG Tablet is not a steroid. It is a Non-Steroidal Anti-Inflammatory Drug (NSAID).

PBREN D 75/20MG Tablet is not recommended for long-term use unless directed by a doctor. Long-term use may increase the risk of side effects.

If your condition does not improve after taking PBREN D 75/20MG Tablet, you should consult your doctor. They can re-evaluate your condition and recommend alternative treatments.

PBREN D 75/20, containing pregabalin 75 mg and duloxetine 20 mg, is primarily used for the management of neuropathic pain. This includes pain due to diabetic peripheral neuropathy, nerve injury, or certain chronic pain conditions where nerve dysfunction is involved. The combination targets pain pathways in the central nervous system to reduce pain intensity and improve function.

Pregabalin in PBREN D 75/20 binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and dampening abnormal nerve firing. Duloxetine inhibits the reuptake of serotonin and norepinephrine, enhancing descending inhibitory pain pathways. Together, these actions decrease the transmission and perception of neuropathic pain.

No. The dose and frequency of PBREN D 75/20 must be determined only by a qualified healthcare professional. Individual requirements vary based on the underlying condition, kidney and liver function, age, concomitant medications, and response to therapy. Self-adjusting the dose or taking it without prescription can increase the risk of serious side effects, withdrawal symptoms, or inadequate pain control.

Common side effects include dizziness, drowsiness, fatigue, dry mouth, nausea, constipation, increased sweating, blurred vision, and weight gain. Some patients may experience peripheral edema (swelling of legs or feet) or mild increase in blood pressure. These effects are often dose-related. If side effects are severe, persistent, or interfere with daily activities, medical review is necessary.

Pregabalin can be associated with dependence and withdrawal-like symptoms if stopped abruptly, especially after long-term or high-dose use. Duloxetine discontinuation may also cause symptoms such as dizziness, irritability, insomnia, headache, and nausea. Therefore, PBREN D 75/20 should not be stopped suddenly. Any change in dose or discontinuation should be gradual and supervised by a healthcare professional.

Pregabalin is primarily eliminated by the kidneys, so patients with reduced kidney function may require dose adjustments or alternative regimens, as determined by their clinician. Use in moderate to severe renal impairment must be individualized, and kidney function should be assessed before and periodically during treatment. Patients should not modify the dose on their own.

Data on the use of pregabalin and duloxetine in pregnancy are limited, and both medicines may pose potential risks to the fetus. PBREN D 75/20 should be used during pregnancy only if the potential benefit justifies the potential risk, after careful assessment by an obstetrician or relevant specialist. Pregnant women or those planning pregnancy should not start or continue this medicine without medical advice.

Both pregabalin and duloxetine can be excreted into breast milk to varying degrees. The potential effects on the breastfed infant, including sedation, poor feeding, or irritability, are not fully characterized. Breastfeeding while taking PBREN D 75/20 requires an individualized risk–benefit assessment by a healthcare professional. In some cases, alternative therapies or cessation of breastfeeding may be recommended.

Alcohol can enhance the central nervous system depressant effects of pregabalin and duloxetine, leading to increased dizziness, drowsiness, impaired concentration, and risk of falls or accidents. Regular or heavy alcohol intake also increases the risk of liver injury with duloxetine. Patients are generally advised to avoid or strictly limit alcohol consumption while taking PBREN D 75/20 and to discuss their alcohol use with their clinician.

PBREN D 75/20 can cause dizziness, drowsiness, blurred vision, and slowed reaction times, especially when treatment is initiated or doses are changed. These effects may impair the ability to drive, operate machinery, or perform tasks requiring alertness. Patients should avoid such activities until they know how the medicine affects them and should follow their clinician’s advice regarding driving safety.

If a dose is missed, it should generally be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Two doses should not be taken at the same time to compensate for a missed dose. For repeated missed doses or uncertainty, patients should consult their prescriber or pharmacist.

Serious but less common risks include suicidal thoughts or behavior, severe mood changes, serotonin syndrome when combined with other serotonergic drugs, significant liver injury (mainly related to duloxetine), severe allergic reactions, and marked dizziness or sedation leading to falls. Any new or worsening depression, unusual behavior, jaundice, dark urine, severe rash, swelling of the face or tongue, or difficulty breathing requires immediate medical attention.